title: Purification and characterization of a novel subtype a3 botulinum neurotoxin.
abstract: Botulinum neurotoxins (BoNTs) produced by Clostridium botulinum are of considerable importance due to their being the cause of human and animal botulism, their potential as bioterrorism agents, and their utility as important pharmaceuticals. Type A is prominent due to its high toxicity and long duration of action. Five subtypes of type A BoNT are currently recognized; BoNT/A1, -/A2, and -/A5 have been purified, and their properties have been studied. BoNT/A3 is intriguing because it is not effectively neutralized by polyclonal anti-BoNT/A1 antibodies, and thus, it may potentially replace BoNT/A1 for patients who have become refractive to treatment with BoNT/A1 due to antibody formation or other modes of resistance. Purification of BoNT/A3 has been challenging because of its low levels of production in culture and the need for innovative purification procedures. In this study, modified Mueller-Miller medium was used in place of traditional toxin production medium (TPM) to culture C. botulinum A3 (CDC strain) and boost toxin production. BoNT/A3 titers were at least 10-fold higher than those produced in TPM. A purification method was developed to obtain greater than 95% pure BoNT/A3. The specific toxicity of BoNT/A3 as determined by mouse bioassay was 5.8 × 10(7) 50% lethal doses (LD(50))/mg. Neutralization of BoNT/A3 toxicity by a polyclonal anti-BoNT/A1 antibody was approximately 10-fold less than the neutralization of BoNT/A1 toxicity. In addition, differences in symptoms were observed between mice that were injected with BoNT/A3 and those that were injected with BoNT/A1. These results indicate that BoNT/A3 has novel biochemical and pharmacological properties compared to those of other subtype A toxins.
authors.affiliation: Department of Bacteriology, Food Research Institute, University of Wisconsin--Madison, Madison, Wisconsin, USA. eajohnso@wisc.edu
authors.forename: William H
authors.initials: WH
authors.lastname: Tepp
authors.forename: Guangyun
authors.initials: G
authors.lastname: Lin
authors.forename: Eric A
authors.initials: EA
authors.lastname: Johnson
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000992:Antitoxins / Q000276:immunology; D001681:Biological Assay; D019274:Botulinum Toxins, Type A / Q000302:isolation & purification* / Q000633:toxicity*; D001906:Botulism / Q000401:mortality / Q000473:pathology; D003014:Clostridium botulinum / Q000737:chemistry*; D003470:Culture Media / Q000737:chemistry; D004195:Disease Models, Animal; D007928:Lethal Dose 50; D051379:Mice; D009500:Neutralization Tests
chemical_list: D000907:Antibodies, Bacterial; D000992:Antitoxins; D003470:Culture Media; D019274:Botulinum Toxins, Type A